Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Study of Azvudine and Dolutegravir in Healthy Subjects
NCT07002229Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azvudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 27, Time to Maximum Plasma Concentration at Steady State at Day 27 and 1 more. Started Dec 2021; status: completed.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07002229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002229.